OC
OTLK icon

Oppenheimer & Co’s Outlook Therapeutics OTLK Stock Holding History

Oppenheimer & Co’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.3K Sell
14,000
-1,500
-10% -$930 ﹤0.01% 1753
2026
Q1 		$3.19K Buy
+15,500
New +$6.7K ﹤0.01% 1681
2025
Q4 		– Sell
-13,000
Closed -$13.8K – 1696
2025
Q3 		$13.8K Sell
13,000
-1,700
-12% -$2.94K ﹤0.01% 1643
2025
Q2 		$23.5K Buy
14,700
+1,200
+9% +$1.91K ﹤0.01% 1592
2025
Q1 		$16.5K Buy
+13,500
New +$23.7K ﹤0.01% 1555
2024
Q1 		– Sell
-1,055
Closed -$8.31K – 1494
2023
Q4 		$8.31K Sell
1,055
-175
-14% -$1.48K ﹤0.01% 1382
2023
Q3 		$5.44K Buy
1,230
+550
+81% +$12.2K ﹤0.01% 1374
2023
Q2 		$23.7K Sell
680
-460
-40% -$12.5K ﹤0.01% 1400
2023
Q1 		$24.9K Buy
1,140
+25
+2% +$559 ﹤0.01% 1359
2022
Q4 		$24.1K Buy
1,115
+215
+24% +$4.68K ﹤0.01% 1329
2022
Q3 		$22K Buy
900
+200
+29% +$4.65K ﹤0.01% 1342
2022
Q2 		$14K Buy
+700
New +$20.1K ﹤0.01% 1395
2022
Q1 		– Sell
-1,105
Closed -$30K – 1553
2021
Q4 		$30K Buy
1,105
+460
+71% +$16.4K ﹤0.01% 1478
2021
Q3 		$28K Sell
645
-35
-5% -$1.69K ﹤0.01% 1479
2021
Q2 		$34K Buy
680
+25
+4% +$1.16K ﹤0.01% 1494
2021
Q1 		$29K Buy
+655
New +$25.1K ﹤0.01% 1425
2020
Q4 		– Sell
-500
Closed -$7K – 1385
2020
Q3 		$7K Buy
+500
New +$11.1K ﹤0.01% 1273
2020
Q2 		– Sell
-575
Closed -$7K – 1302
2020
Q1 		$7K Buy
+575
New +$9.54K ﹤0.01% 1186

Other funds holding OTLK

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
GWM
Gilpin Wealth Management Denver, Colorado $145M AUM

Oppenheimer & Co's OTLK Position: Q2 2026 in Review

Oppenheimer & Co reduced its Outlook Therapeutics (OTLK) stake by 9.7% in Q2 2026, selling an estimated $930 and leaving 14,000 shares worth $22.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1753.

Oppenheimer & Co first reported a position in OTLK in Q1 2020 and has held it in 18 quarters since. The position peaked at $34K in Q2 2021. 69 funds tracked by Wall St. Rank hold OTLK as of Q2 2026.

  • Oppenheimer & Co held 14,000 shares of Outlook Therapeutics worth $22.3K as of Q2 2026.
  • Oppenheimer & Co sold 1,500 Outlook Therapeutics shares in Q2 2026, an estimated $930.
  • Outlook Therapeutics made up ﹤0.01% of Oppenheimer & Co's portfolio in Q2 2026, its #1753 holding.
  • Oppenheimer & Co first reported a position in Outlook Therapeutics in Q1 2020 and has held it in 18 quarters since.
  • Oppenheimer & Co's Outlook Therapeutics position peaked at $34K in Q2 2021.
  • 69 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2026.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.